bioMerieux' 2008 sales rise 4.5% to $1.4B
French diagnostics firm bioMerieux says net sales amounted to 1.11 billion euros ($1.4 billion) in 2008, an increase of 7.5% from the year before, at constant exchange rates, which is in line with its 2012 strategic plan objectives.
Including the effects of new business development agreements, the period-on-period increase was 9.8%. Fourth-quarter 2008 net sales came to 311 million euros, a like-for-like increase of 8.1% over the year-earlier period.
Net debt stood at 50.0 million euros at December 31, 2008, after the dividend payment and the acquisition of AB Biodisk, AviaraDx and PML Microbiologicals. Net cash amounted to 15.0 million euros at year-end 2007.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze